4 questions key to making sense of new data on Biogen’s Alzheimer’s drug

4 questions key to making sense of new data on Biogen’s Alzheimer’s drug

STAT Plus: 4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug

By REBECCA ROBBINS

RUBY WALLAU FOR STAT

Biogen is set to give a highly anticipated presentation detailing data from two late-stage clinical trials of its drug, known as aducanumab.

READ MORE